Mizuho downgraded shares of Athira Pharma (NASDAQ:ATHA – Free Report) from an outperform rating to a neutral rating in a research report report published on Thursday, Marketbeat Ratings reports. They currently have $0.50 price objective on the stock, down from their prior price objective of $5.00.
Several other research firms also recently commented on ATHA. Rodman & Renshaw downgraded Athira Pharma from a buy rating to a neutral rating in a research report on Wednesday, September 4th. BTIG Research cut Athira Pharma from a buy rating to a neutral rating in a research report on Wednesday, September 4th. Finally, JMP Securities cut shares of Athira Pharma from an outperform rating to a market perform rating in a research report on Wednesday, September 4th.
View Our Latest Research Report on ATHA
Athira Pharma Price Performance
Athira Pharma (NASDAQ:ATHA – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. As a group, equities analysts anticipate that Athira Pharma will post -2.56 earnings per share for the current fiscal year.
Insider Activity at Athira Pharma
In related news, Director Kelly A. Romano acquired 27,400 shares of the stock in a transaction on Monday, June 24th. The shares were purchased at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the purchase, the director now directly owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 8,829 shares of company stock worth $5,033. Company insiders own 19.80% of the company’s stock.
Institutional Trading of Athira Pharma
Large investors have recently modified their holdings of the stock. Private Advisor Group LLC bought a new stake in Athira Pharma during the fourth quarter worth about $32,000. Rothschild Investment LLC bought a new stake in shares of Athira Pharma during the 2nd quarter worth approximately $34,000. Mirador Capital Partners LP acquired a new stake in shares of Athira Pharma during the 1st quarter worth approximately $57,000. XTX Topco Ltd bought a new position in Athira Pharma in the second quarter valued at approximately $60,000. Finally, Invst LLC acquired a new position in Athira Pharma during the second quarter valued at approximately $68,000. 57.12% of the stock is owned by institutional investors and hedge funds.
Athira Pharma Company Profile
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.
Featured Stories
- Five stocks we like better than Athira Pharma
- What is MarketRank™? How to Use it
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
- What is the Hang Seng index?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.